Acly-KO Mouse
Common Name
Acly-KO
제품 ID
S-KO-17853
Backgroud
C57BL/6JCya
품종 계통계통 ID
KOCMP-104112-Acly-B6J-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Acly-KO Mouse (카탈로그 번호 S-KO-17853)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Acly-KO
품종 계통계통 ID
KOCMP-104112-Acly-B6J-VA
유전자명
제품 ID
S-KO-17853
유전자 별칭
A730098H14Rik
배경
C57BL/6JCya
NCBI ID
변형 내용
Conventional knockout
염색체
Chr 11
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000007131
NCBI 전사체 ID
NM_134037
타겟 영역
Exon 4~6
유효 영역 크기
~2.5 kb
유전자 연구 개요
Acly, also known as adenosine 5'-triphosphate citrate lyase, is a cytosolic enzyme that converts citrate into acetyl-coenzyme A. This reaction is crucial for fatty acid and cholesterol biosynthesis, linking carbohydrate to lipid metabolism [1,2]. It is also involved in protein acetylation, and its expression changes are related to hyperlipidemia, cardiovascular diseases, and cancer [8]. Genetic models, such as gene knockout (KO) or conditional knockout (CKO) mouse models, have been valuable in studying its functions.
In cancer research, ACLY inhibition in immunocompetent mice was found to up-regulate PD-L1 expression in cancer cells, inducing T-cell dysfunction and immunosuppression. However, it also overcame cancer resistance to anti-PD-L1 therapy in a cGAS-dependent manner, likely due to polyunsaturated fatty acid peroxidation and mitochondrial DNA leakage that activates the cGAS-STING pathway [1]. In lipid metabolism and atherosclerosis studies, ACLY deficiency in hepatocytes protected from hepatic steatosis and dyslipidemia. Pharmacological inhibition of ACLY by bempedoic acid prevented dyslipidemia and attenuated atherosclerosis in hypercholesterolemic mice and miniature pigs [2]. In colon cancer, ACLY-deficient cell lines showed attenuated migration and invasion abilities, and ACLY promoted metastasis by stabilizing CTNNB1 protein [3]. In non-alcoholic fatty liver disease (NAFLD), Hrd1 interacted with and ubiquitinated Acly, reducing its protein level and suppressing lipogenesis, with Hrd1 overexpression ameliorating hepatic steatosis in db/db mice [4]. In hepatic ischemia-reperfusion injury, hepatic deficiency of Acly exacerbated injury, while restoration of Acly nuclear localization in the steatotic liver ameliorated the injury [5]. In oocyte maturation, autophagy in granulosa cells selectively degraded ACLY to maintain citrate homeostasis and promote oocyte maturation [6]. In CD8 T-cell function, ablation of ACLY triggered an alternative acetate-dependent pathway for acetyl-CoA production, and ACLY and ACSS2 coordinated cytosolic acetyl-CoA production to maintain chromatin accessibility and T-cell effector function [7]. In experimental colitis, ACLY-deficient CD4+ T cells showed an impaired capacity to induce intestinal inflammation, and butyrate suppressed ACLY expression in T cells, with tributyrin ameliorating chronic colitis [9].
In conclusion, Acly plays essential roles in multiple biological processes, including lipid metabolism, cancer development, oocyte maturation, and immune cell function. Gene knockout or conditional knockout mouse models have been instrumental in revealing its functions in diseases such as cancer, atherosclerosis, NAFLD, hepatic ischemia-reperfusion injury, and experimental colitis, providing potential therapeutic targets for these conditions.
References:
1. Xiang, Wei, Lv, Hongwei, Xing, Fuxue, Yang, Wen, Wang, Hongyang. 2023. Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation. In Science advances, 9, eadi2465. doi:10.1126/sciadv.adi2465. https://pubmed.ncbi.nlm.nih.gov/38055816/
2. Feng, Xiaojun, Zhang, Lei, Xu, Suowen, Shen, Ai-Zong. 2019. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review. In Progress in lipid research, 77, 101006. doi:10.1016/j.plipres.2019.101006. https://pubmed.ncbi.nlm.nih.gov/31499095/
3. Wen, Jun, Min, Xuejie, Shen, Mengqin, Liu, Jianjun, Zhao, Xiaoping. 2019. ACLY facilitates colon cancer cell metastasis by CTNNB1. In Journal of experimental & clinical cancer research : CR, 38, 401. doi:10.1186/s13046-019-1391-9. https://pubmed.ncbi.nlm.nih.gov/31511060/
4. Li, Kai, Zhang, Kaini, Wang, Hai, Liang, Xiubin, Su, Dongming. 2020. Hrd1-mediated ACLY ubiquitination alleviate NAFLD in db/db mice. In Metabolism: clinical and experimental, 114, 154349. doi:10.1016/j.metabol.2020.154349. https://pubmed.ncbi.nlm.nih.gov/32888949/
5. Gao, Wenbin, Zhang, Liping, Li, Ziru, Mulholland, Michael W, Zhang, Weizhen. 2023. Nuclear Acly protects the liver from ischemia-reperfusion injury. In Hepatology (Baltimore, Md.), 80, 1087-1103. doi:10.1097/HEP.0000000000000692. https://pubmed.ncbi.nlm.nih.gov/37983829/
6. He, Hainan, Wang, Junling, Mou, Xingmei, Zhou, Jilong, Miao, Yi-Liang. 2022. Selective autophagic degradation of ACLY (ATP citrate lyase) maintains citrate homeostasis and promotes oocyte maturation. In Autophagy, 19, 163-179. doi:10.1080/15548627.2022.2063005. https://pubmed.ncbi.nlm.nih.gov/35404187/
7. Kaymak, Irem, Watson, McLane J, Oswald, Brandon M, Roy, Dominic G, Jones, Russell G. 2024. ACLY and ACSS2 link nutrient-dependent chromatin accessibility to CD8 T cell effector responses. In The Journal of experimental medicine, 221, . doi:10.1084/jem.20231820. https://pubmed.ncbi.nlm.nih.gov/39150482/
8. Granchi, Carlotta. 2022. ATP-citrate lyase (ACLY) inhibitors as therapeutic agents: a patenting perspective. In Expert opinion on therapeutic patents, 32, 731-742. doi:10.1080/13543776.2022.2067478. https://pubmed.ncbi.nlm.nih.gov/35436171/
9. Schulz-Kuhnt, Anja, Rühle, Katharina, Javidmehr, Asal, Neurath, Markus F, Atreya, Imke. 2024. ATP citrate lyase (ACLY)-dependent immunometabolism in mucosal T cells drives experimental colitis in vivo. In Gut, 73, 601-612. doi:10.1136/gutjnl-2023-330543. https://pubmed.ncbi.nlm.nih.gov/38176897/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
